Synthes To Slide ProDisc Into U.S. Artificial Lumbar Disc Market
This article was originally published in The Gray Sheet
Executive Summary
With FDA approval of Synthes' ProDisc artificial disc Aug. 14 for treatment of degenerative disc disease, the firm becomes the second entrant into the U.S. artificial lumbar disc market after J&J/DePuy (Charité)
You may also be interested in...
CMS Charité Policy Leaves Coverage Option Open For Under-60 Crowd
Johnson & Johnson/Depuy's future just got a little brighter. A CMS coverage decision allows local Medicare contractors the option to pay for its Charité lumbar artificial disc in beneficiaries under 60. But the agency will not allow coverage of the device in older patients
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.